Alliance for Regenerative Medicine Releases Q2 2016 Data Report, Highlighting Sector Trends and Metrics

– August 3, 2016

WASHINGTON, D.C., August 4, 2016 – The Alliance for Regenerative Medicine (ARM) today announced the release of its quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2016.

Using information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from 700+ cell therapy, gene therapy, tissue engineering and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.

The Q2 2016 data report includes sections featuring ARM member organization and key stakeholder perspectives, highlighting important focus areas for the sector:

  • Reimbursement and market access issues for disease-modifying and potentially curative therapies with short-duration dosing regimens, commentary from Josh Carlson, University of Washington; Eric Faulkner, Evidera; and Ted Slocomb, Audentes Therapeutics.
  • The importance of and need for development and implementation of agreed-upon industry-wide standards for the regenerative medicine sector, commentary from Jessica Carmen, MaxCyte; Elena Kfoury, Axiogenesis; Jiwen Zhang, GE Healthcare.

“This sector has shown continued momentum and achieved significant clinical milestones throughout the second quarter of 2016, “ said Morrie Ruffin, ARM’s managing director. “Further, the number of deals and key financings we’ve witnessed in the first half of this year, despite the less than favorable macroeconomic environment, is a testament to the continued progress of these technologies, and the long-term potential of this field.”

Highlighted findings from the Q2 2016 data report include:

  • Globally, companies active in gene and cellular therapies and other regenerative medicines raised more than $2.5 billion in the first half of 2016. The report also includes data broken out by technology and financing type.
  • There were 728 clinical trials underway worldwide at the close of the second quarter of 2016. The report includes figures on clinical trials by phase and indication.
  • Areas of regulatory and legislative focus moving in to Q3 2016, including global reimbursement issues; industry-wide standards development; optimizing the regulatory and review pathways; FDA guidance on minimal manipulation; international regulatory convergence; gene editing and related bioethics issues; PDUFA reauthorization; EU GMP for ATMP and more.

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers and clinical data events.

The report is available online here. For more information, please visit or contact Lyndsey Scull at

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit